Literature DB >> 12878162

Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and nonmalignant MCF12A human breast epithelial cells.

Galatea Kallergi1, Anna Tsapara, Marilena Kampa, Evangelia A Papakonstanti, Kostas Krasagakis, Elias Castanas, Christos Stournaras.   

Abstract

The mechanisms through which opioids regulate the activity of malignant breast epithelial cells are currently unknown. In the present study we report the differential actin cytoskeleton reorganization induced by opioids in malignant (MCF7) and nonmalignant (MCF12A) breast epithelial cells expressing functional opioid receptors. Exposure of MCF7 cells to the opioid agonist alpha(s1) casomorphin induced important actin assembly and reorganization, including the formation of filopodia and lamellipodia. In contrast, incubation of MCF12A cells with alpha(s1) casomorphin revealed a partial but transient disassembly of actin microfilaments. Immunoprecipitation and immunoblot analyses showed rapid phosphorylation of focal adhesion kinase (FAK) and vinculin in opioid-treated MCF7 cells. Moreover, FAK associates with phosphatidylinositol-3 (PI-3 kinase), the latter being subsequently phosphorylated and activated. In addition, a substantial activation of the small GTPase Rac1 was observed. Pretreatment of MCF7 cells with the specific PI-3 kinase inhibitor wortmannin abolished both the activation of Rac1 and actin reorganization, while the opioid-induced phosphorylation of FAK and vinculin remained unaffected. Interestingly, in opioid-treated MCF12A cells this signaling cascade remained inactive, while we identified rapid phosphorylation of actin regulating the protein villin. Finally, opioids differentially inhibited cell motility in each cell line. Our data suggest a distinct, opioid-induced, signaling pathway activated in malignant breast epithelial cells, leading to important actin reorganization. These findings may indicate a potential antineoplastic role of opiates, based on the activation of differential signaling mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878162     DOI: 10.1016/s0014-4827(03)00210-6

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Molecular imaging of phosphorylation events for drug development.

Authors:  C T Chan; R Paulmurugan; R E Reeves; D Solow-Cordero; S S Gambhir
Journal:  Mol Imaging Biol       Date:  2008-12-02       Impact factor: 3.488

2.  Cyclic mechanical stretch decreases cell migration by inhibiting phosphatidylinositol 3-kinase- and focal adhesion kinase-mediated JNK1 activation.

Authors:  Leena P Desai; Steven R White; Christopher M Waters
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

3.  Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells.

Authors:  Galatea Kallergi; Dimitris Mavroudis; Vassilis Georgoulias; Christos Stournaras
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

4.  Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.

Authors:  N Kuzumaki; A Suzuki; M Narita; T Hosoya; A Nagasawa; S Imai; K Yamamizu; H Morita; H Nagase; Y Okada; H J Okano; J K Yamashita; H Okano; T Suzuki; M Narita
Journal:  Br J Cancer       Date:  2012-02-16       Impact factor: 7.640

5.  Analysis of gene expression profiles in HeLa cells in response to overexpression or siRNA-mediated depletion of NASP.

Authors:  Oleg M Alekseev; Richard T Richardson; Oleg Alekseev; Michael G O'Rand
Journal:  Reprod Biol Endocrinol       Date:  2009-05-13       Impact factor: 5.211

6.  Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness.

Authors:  Ariadne Androulidaki; Erini Dermitzaki; Maria Venihaki; Effie Karagianni; Olga Rassouli; Erini Andreakou; Christos Stournaras; Andrew N Margioris; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2009-06-02       Impact factor: 27.401

7.  Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.

Authors:  Galatea Kallergi; Sofia Agelaki; Antonia Kalykaki; Christos Stournaras; Dimitris Mavroudis; Vassilis Georgoulias
Journal:  Breast Cancer Res       Date:  2008-09-29       Impact factor: 6.466

8.  The effects of naloxone on human breast cancer progression: in vitro and in vivo studies on MDA.MB231 cells.

Authors:  Sabrina Bimonte; Antonio Barbieri; Marco Cascella; Domenica Rea; Giuseppe Palma; Vitale Del Vecchio; Cira Antonietta Forte; Francesco Del Prato; Claudio Arra; Arturo Cuomo
Journal:  Onco Targets Ther       Date:  2018-01-03       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.